Drug recall · November 18, 2020
Bupivacaine Hydrochloride in 8.25% Dextrose Injection recall
Why: Presence of particulate matter in solution - black and transparent particles
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bupivacaine Hydrochloride in 8.25% Dextrose Injection, USP Spinal 0.75% (15 mg/2 mL) 10 x 2 mL single-dose ampules, Rx only, Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 USA, Manufactured by: Baxter Pharmaceuticals India Private Ltd Ahmedabad 382213 India, NDC 36000-092-10
- Lots / codes
Lot #: A0B1241, Exp 10/2020; A0C0091, Exp 12/2020; A0D0268, Exp 02/2022
- Company
- Baxter Healthcare Corporation, Deerfield, IL
- Distribution
- Nationwide USA
- Initiated
- October 7, 2020 · Voluntary: Firm initiated
- Classified
- November 12, 2020
- Reported
- November 18, 2020
- Ended
- May 22, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupivacaine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.